Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: An interphase cytogenetic study

Journal of the American College of Surgeons

Volumn 190, Issue 5, 2000, Pages 530-539

  Botti, Claudio ^a   Pescatore, Barbara ^b   Mottolese, Marcella ^b   Sciarretta, Francesco ^b   Greco, Claudia ^b   Di Filippo, Franco ^b   Gandolfo, Giuseppe Maria ^b   Cavaliere, Francesco ^a   Bovani, Roberta ^b   Varanese, Antonio ^b   Cianciulli, Anna Maria ^b  

^a Department of Surgical Oncology ^*  (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CHROMOSOME 1; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL;

EID: 0034096685     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1072-7515(00)00252-0     Document Type: Article

References (50)

1. Brinkley D, Haybittle JL. Causes of death among long-term survivors from breast cancer in Connecticut. World J Surg 1977; 1:287-289.
2. Ciatto S, Bonardi R. Is breast cancer ever cured? Follow-up study of 5623 breast cancer patients. Tumori 1991;77:465-467.
3. Dooley WC. Surgery for breast cancer. Curr Opin Oncol 1998; 10:504-512.
4. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-effect of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-1471.
5. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
6. Morrow M. Identification of the woman at risk for breast cancer: problem solved? Recent Results Cancer Res 1999;151:85-95.
7. Page DL, Dupont WD. Anatomical markers of human premalignancy and risk of breast cancer. Cancer 1990;66:1326-1335.
8. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breast. Hum Pathol 1985;16: 796-807.
9. Dairkee SH, Smith HS. Genetic analysis of breast cancer progression. J Mamm Gland Biol Neoplasia 1996;1:139-152.
10. Bièche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995;14:227-251.
11. Killen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast: a comparison with histologic features. Cancer 1991;68:2602-2607.
12. Sandberg AA. Cancer cytogenetics for clinicians. CA Cancer J Clin 1991;44:136-159.
13. Devilee P, Cornelisse CJ. Somatic changes in human breast cancer. Biochim Biophys Acta 1994;1198:113-130.
14. Dutrillax B, Gerbault-Sererau M, Remvikos Y, et al. Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 1991;19:245-255.
15. Harrison MM, Magee HM, Loughlin JFO, et al. Comparison of chromosome 1 aneusomy detected by interphase cytogenetics and DNA ploidy in carcinoma of the breast. Histopathology 1997;30:221-226.
16. Mendelin J, Grayson M, Wallis T, Visscher DW. Analysis of chromosome in situ aneuploidy in breast carcinoma progression by using fluorescent in situ hybridization. Lab Invest 1999;79: 387-393.
17. Dawson LA, Chow E, Goss PE. Evolving concepts in contralateral breast cancer. Eur J Cancer 1998;34:2000-2009.
18. Mark HFL. Interphase cytogenetics for studying solid tumors. Cancer 1998;83:839-843.
19. Cajulis RS, Frias-Hidvegi D. Detection of numerical chromosomal abnormalities in malignant cells in fine needle aspirates by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes. Acta Cytol 1993;37:391-396.
20. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
21. Nowell PC. The clonal evolution of tumour cell populations. Science 1976;194:23-28.
22. Hittelman WN, Kim HJ, Lee JS, et al. Detection of chromosome instability of tissue fields at risk: in situ hybridization. J Cell Biochem 1996;25S:57-62.
23. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
24. Neft RE, Crowell RE, Gilliland FD, et al. Frequency of trisomy 20 in nonmalignant bronchial epithelium from lung cancer patients and cancer-free former uranium miners and smokers. Cancer Epidemiol Biomarkers Prev 1998;7:1051-1504.
25. Persons DL, Croughan WS, Borelli KA, Cherian R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998;106:11-17.
26. Bulten J, Poddighe PJ, Robben JC, et al. Interphase cytogenetic analysis of cervical intraepithelial neoplasia. Am J Pathol 1998; 152:495-503.
27. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-278.
28. Visscher DW, Wallis TL, Crissman JD. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics. Cancer 1996;77:315-320.
29. O'Connel P, Pekkel V, Fuqua S, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
30. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinoma. Science 1996;274: 2057-2059.
31. Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res 1996;56:287-293.
32. Widschwenter M, Berger J, Daxenbichler G, et al. Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997;57:4158-4161.
33. Shackney SE, Singh SG, Yakulis R, et al. Aneuploidy in breast cancer: a fluorescence in situ hybridization study. Cytometry 1995;22:282-291.
34. Person DL, Robinson RA, Hsu PH, et al. Chromosome-specific aneusomy in carcinoma of the breast. Clin Cancer Res 1996;2: 883-888.
35. Mark HFL, Taylor W, Afify A, et al. Stage I and stage II infiltrating ductal carcinoma of the breast analyzed for chromosome 8 copy number using fluorescent in situ hybridization. Pathobiology 1997;65:184-189.
36. Mark HFL, Brown S, Taylor W, et al. Study of chromosome 12 copy number in breast cancer using fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;108:26-31.
37. Adeyinka A, Mertens F, Idvall I, et al. Multiple polysomies in breast carcinomas: preferential gain of chromosomes 1, 5, 6, 7, 12, 16, 17, 18, and 19. Cancer Genet Cytogenet 1999;111:144-148.
38. Ichikava D, Hashimoto N, Hoshima M, et al. Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 1996;77:2064-2069.
39. Tsuda H, Takarabe T, Shimamura K, Hirohashi S. Detection of alterations in chromosomes 16 and 1 by fluorescence in situ hybridization in breast tumors cytologically or histologically equivocal for malignancy. Pathobiology 1998;66:268-273.
40. Meisner LF. Assessing aneuploidy in normal tissues with FISH: pitfalls and insights. Cancer Genet Cytogenet 1994;72:78-80.
41. Laundin C, Mertens F. Cytogenetics or benign breast lesions. Breast Cancer Res Treat 1998;51:1-15.
42. Verdoodt B, Castelain P, Bourgain C, Kirsch-Volders M. Aneuploidy for chromosome 1 and overall DNA content in benign and malignant breast disease. Cancer Genet Cytogenet 1994;78: 53-63.
43. Anastasi J. Interphase cytogenetic analysis in the diagnosis and study of neoplastic disorders. Am J Clin Pathol 1991;95:522-528.
44. Sneige N, Sahin A, Dihn M, El-Naggar A. Interphase cytogenetics in mammographically detected breast lesions. Hum Pathol 1996;27:330-335.
45. Simpson JF, Quan DE, Ho JP, Slovack ML. Genetic heterogeneity of primary and metastatic breast carcinoma detected by fluorescent in situ hybridization. Am J Pathol 1996;149:751-758.
46. Visscher DW, Wallis T, Ritchie CA. Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry 1995;21:95-100.
47. Larson PS, de las Morenas A, Cupples LA, et al. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 1998;152:1591-1598.
48. Fabian CJ, Kamel S, Zalles C, Kimler BF. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem 1996;25S:112-122.
49. Rohan TE, Harwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90: 1262-1269.
50. Euhus DM, Maitra A, Wistuba II, et al. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer. J Surg Res 1999;83:13-18.